Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises
Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia
Highlighted progress across portfolio at inaugural Research and Development (R&D) Day
Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization
Cash balance of $395.9 million positions company with runway through the third quarter of 2024
https://finance.yahoo.com/news/forma-therapeutics-reports-second-quarter-110000892.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.